Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)

This phase II trial tests how well giving botensilimab and balstilimab prior or to surgery (neoadjuvent) works for the treatment of colorectal cancer that may …

Advanced Colon AdenocarcinomaAdvanced Colorectal AdenocarcinomaAdvanced Rectal Adenocarcinoma+10 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT07595874

Phase 2

A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma

The study researchers believe that a combination of the drugs trastuzumab and tucatinib, given with standard chemotherapy (capecitabine and oxaliplatin/FOLFOX)…

Adenocarcinoma of the RectumLocally Advanced Rectal AdenocarcinomaRectal Adenocarcinoma+2 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT05672524

Phase 1

DINOMITE (Decreasing Hypoxia With Mitochondrial Inhibition in Locally Advanced Rectal Cancer): Phase 1 Trial of Papaverine in Combination With Radiation

This phase I trial studies the side effects and best dose of papaverine (PPV) when given together with radiation therapy (RT) and tests how well it works in tr…

Locally Advanced Rectal AdenocarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8

Estimated

~$150 – $3,000

Actual pay is set by the research site.

City of Hope Medical CenterNCT06834126

Phase 2

A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma

The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or…

Microsatellite Stable Rectal CarcinomaLocally Advanced Rectal Adenocarcinoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT06843434

Phase 2

ULtra sensiTive ctDNA-Informed Management eArly-stage recTal cancEr (ULTIMATE)

This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signa…

Rectal AdenocarcinomaRectal CancerEarly-stage Rectal Cancer+1 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

University of California, DavisNCT07209215